SPY759.06+0.26%QQQ690.90+0.40%BTC/USD68,438.77−4.11%DIA523.26+0.15%GLD355.86+0.27%TLT79.57−0.19%
BenzingaPremium Services
Premium Services

Biotech

FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report
FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial
Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial
Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial
Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030
Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030
Johnson & Johnson Reports Favorable Data For Bipolar Study
Johnson & Johnson Reports Favorable Data For Bipolar Study

Biotech Recent News

Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones
Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones
Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.
Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities
Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities
Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales
Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales
Pfizer and Blackstone Life Sciences signed a $1.5 billion deal to fund berobenatide, a monthly GLP-1 obesity drug entering 10 Phase 3 trials in 2026.
Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial
Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial
Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
Exicure agrees to sell its GPC-100 program assets to GPCRT for $4.8 million to maximize stockholder value.
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Amgen reported positive Phase 3 OASIZ-301 trial data for dazodalibep, showing significant reductions in systemic Sjögren's disease activity.
PepGen Stock Doubles in One Session - Here's Why
PepGen Stock Doubles in One Session - Here's Why
PepGen reports positive Phase 2 results for PGN-EDODM1 in DM1, showing record splicing correction and notable functional improvements.
Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine
Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine
Valneva reports 94% of adults sustained antibody protection five years after receiving its single-dose chikungunya shot IXCHIQ.
Why Is Black Diamond Therapeutics Stock Soaring Tuesday?
Why Is Black Diamond Therapeutics Stock Soaring Tuesday?
Black Diamond Therapeutics reports Phase 2 silevertinib data, outlines FDA Phase 3 plans, and confirms cash runway extending into late 2028.
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
Ionis Pharmaceuticals stock hits a 52-week low after halving 2026 Tryngolza guidance, despite beating Q3 earnings estimates and posting 55% revenue growth.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved